Shin Hwa Kyoung, Kim Yong Ki, Kim Ki Young, Lee Jeong Hyun, Hong Ki Whan
Department of Pharmacology, College of Medicine, Pusan National University, Pusan, Korea.
Circulation. 2004 Mar 2;109(8):1022-8. doi: 10.1161/01.CIR.0000117403.64398.53. Epub 2004 Feb 16.
Remnant lipoprotein particles (RLPs), products of lipolytic degradation of triglyceride-rich lipoprotein derived from VLDL, exert atherogenesis. In this study, we observed how RLPs induced cytotoxicity in human umbilical vein endothelial cells (HUVECs) and cilostazol prevented cell death.
RLPs were isolated from the plasma of hyperlipidemic patients by use of an immunoaffinity gel mixture of anti-apolipoprotein A-1 and anti-apolipoprotein B-100 monoclonal antibodies. RLPs (50 microg/mL) significantly increased superoxide formation in HUVECs associated with elevated gp91phox mRNA and protein expression and Rac1 translocation, accompanied by increased production of tumor necrosis factor (TNF)-alpha and interleukin-1beta, DNA fragmentation, and cell death. Cilostazol (1 to 100 micromol/L) significantly suppressed not only NAD(P)H oxidase-dependent superoxide production but also TNF-alpha and interleukin-1beta release and restored viability. RLPs activated a lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), which was not inhibited by cilostazol. Treatment of HUVECs with monoclonal antibody for LOX-1 attenuated RLP-mediated production of superoxide, TNF-alpha, and interleukin-1beta and DNA fragmentation.
RLPs stimulated NAD(P)H oxidase-dependent superoxide formation and induction of cytokines in HUVECs via activation of LOX-1, consequently leading to reduction in cell viability with DNA fragmentation, and cilostazol exerts a cell-protective effect by suppressing these variables.
残余脂蛋白颗粒(RLPs)是极低密度脂蛋白(VLDL)衍生的富含甘油三酯脂蛋白脂解降解的产物,具有致动脉粥样硬化作用。在本研究中,我们观察了RLPs如何诱导人脐静脉内皮细胞(HUVECs)产生细胞毒性以及西洛他唑如何预防细胞死亡。
通过使用抗载脂蛋白A-1和抗载脂蛋白B-100单克隆抗体的免疫亲和凝胶混合物从高脂血症患者血浆中分离RLPs。RLPs(50μg/mL)显著增加HUVECs中的超氧化物形成,这与gp91phox mRNA和蛋白表达升高以及Rac1易位相关,同时伴有肿瘤坏死因子(TNF)-α和白细胞介素-1β产生增加、DNA片段化和细胞死亡。西洛他唑(1至100μmol/L)不仅显著抑制烟酰胺腺嘌呤二核苷酸磷酸(NAD(P)H)氧化酶依赖性超氧化物产生,还抑制TNF-α和白细胞介素-1β释放并恢复细胞活力。RLPs激活凝集素样氧化型低密度脂蛋白受体-1(LOX-1),而西洛他唑对此无抑制作用。用LOX-1单克隆抗体处理HUVECs可减弱RLP介导的超氧化物、TNF-α和白细胞介素-1β产生以及DNA片段化。
RLPs通过激活LOX-1刺激HUVECs中NAD(P)H氧化酶依赖性超氧化物形成并诱导细胞因子产生,进而导致细胞活力降低和DNA片段化,而西洛他唑通过抑制这些变量发挥细胞保护作用。